Written by Phil Cerroni
ClubCorp, announced that the 2012 ClubCorp Charity Classic, the company’s major annual philanthropic open-house event, raised a record-breaking $2.07 million for a variety of charities throughout the U.S.
Nearly 14,000 individuals at 126 ClubCorp properties attended a variety of fundraising events and activities that included more than 100 golf and tennis tournaments and events, and dozens of formal and informal dinners, concerts, swim-a-thons, chef competitions, cookouts and auctions at clubs throughout the country.
Three DFW-area clubs were among the company’s top 10 in total dollars raised, including Gleneagles Country Club ($72,294), Walnut Creek Country Club ($53,854) and La Cima Club ($42,369). In all, area clubs raised $390,098.
During the annual Charity Classic events, private clubs within the ClubCorp family of clubs open their doors to the general public and communities to support many important causes. The Charity Classic also includes an online auction that offers, among other things, international and national getaways, golf packages, dining experiences, and art.
Since its inception in 2007, ClubCorp’s Charity Classic has raised more than $10 million benefitting charities including MDA’s Augie’s Quest, Susan G. Komen for the Cure, Boys and Girls Clubs, Make-a-Wish Foundation and the Employee Partners Care Foundation.
“I am extremely proud that we raised a record-breaking $2.07 million during this year’s Charity Classic – an amazing 25 percent increase over last year – and would like to thank our clubs, members, employees and sponsors, who have come together with their communities to support so many great causes,” said Eric Affeldt, ClubCorp president and CEO. “This initiative has always been close to my heart and is a strong reflection of ClubCorp’s commitment to Building Relationships and Enriching Lives.”
“I’m extremely grateful for the continued support from the ClubCorp family,” said Augie Nieto, chief inspiration officer, Augie's Quest, and co-chair of MDA's ALS division. “The long-term partnership has allowed us to meet exciting research milestones. In 2012, we discovered and are set to launch a Phase 2A clinical trial of Gilenya in ALS Patients. We also expanded the research institute at ALS TDI, tripling the size of our in vivo drug screening capabilities. I see 2013 as a year of momentum and hope for ALS families thanks to the dedication of ClubCorp and the members and employees.”